Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis

Muscle Nerve. 2018 Aug;58(2):261-269. doi: 10.1002/mus.26106. Epub 2018 Mar 25.


Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis.

Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters.

Results: We identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR-320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis.

Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261-269, 2018.

Keywords: ALS; biomarkers; disease comparisons; longitudinal analysis; microRNA; serum.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Alzheimer Disease / blood
  • Alzheimer Disease / physiopathology
  • Amyotrophic Lateral Sclerosis / blood*
  • Amyotrophic Lateral Sclerosis / physiopathology*
  • Biomarkers / blood
  • Cohort Studies
  • Cross-Sectional Studies
  • Disease Progression
  • Female
  • Gene Expression Regulation
  • Humans
  • Longitudinal Studies
  • Male
  • MicroRNAs / blood*
  • Middle Aged
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / physiopathology


  • Biomarkers
  • MicroRNAs